230 related articles for article (PubMed ID: 31783313)
41. Next-Generation Sequencing-Based Detection of Germline Copy Number Variations in BRCA1/BRCA2: Validation of a One-Step Diagnostic Workflow.
Schmidt AY; Hansen TVO; Ahlborn LB; Jønson L; Yde CW; Nielsen FC
J Mol Diagn; 2017 Nov; 19(6):809-816. PubMed ID: 28822785
[TBL] [Abstract][Full Text] [Related]
42. Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients.
Wei Y; Wu J; Gu W; Qin X; Dai B; Lin G; Gan H; Freedland SJ; Zhu Y; Ye D
Eur Urol; 2019 Sep; 76(3):280-283. PubMed ID: 31248605
[TBL] [Abstract][Full Text] [Related]
43. AGO Austria recommendations for genetic testing of patients with ovarian cancer.
Marth C; Hubalek M; Petru E; Polterauer S; Reinthaller A; Schauer C; Scholl-Firon T; Singer CF; Zschocke J; Zeimet AG
Wien Klin Wochenschr; 2015 Aug; 127(15-16):652-4. PubMed ID: 26109557
[TBL] [Abstract][Full Text] [Related]
44. Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy.
Walsh CS
Gynecol Oncol; 2015 May; 137(2):343-50. PubMed ID: 25725131
[TBL] [Abstract][Full Text] [Related]
45. BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing.
Mitri ZI; Jackson M; Garby C; Song J; Giordano SH; Hortobágyi GN; Singletary CN; Hashmi SS; Arun BK; Litton JK
Oncologist; 2015 Jun; 20(6):593-7. PubMed ID: 25948675
[TBL] [Abstract][Full Text] [Related]
46. G84E mutation in HOXB13 is firmly associated with prostate cancer risk: a meta-analysis.
Huang H; Cai B
Tumour Biol; 2014 Feb; 35(2):1177-82. PubMed ID: 24026887
[TBL] [Abstract][Full Text] [Related]
47. Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia.
Krivokuca A; Boljevic I; Jovandic S; Magic Z; Mandic A; Tomasevic Z; Brankovic-Magic M
J Hum Genet; 2019 Apr; 64(4):281-290. PubMed ID: 30651582
[TBL] [Abstract][Full Text] [Related]
48. Prostate cancer: germline prediction for a commonly variable malignancy.
Bambury RM; Gallagher DJ
BJU Int; 2012 Dec; 110(11 Pt C):E809-18. PubMed ID: 22974436
[TBL] [Abstract][Full Text] [Related]
49. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
Giri VN; Knudsen KE; Kelly WK; Cheng HH; Cooney KA; Cookson MS; Dahut W; Weissman S; Soule HR; Petrylak DP; Dicker AP; AlDubayan SH; Toland AE; Pritchard CC; Pettaway CA; Daly MB; Mohler JL; Parsons JK; Carroll PR; Pilarski R; Blanco A; Woodson A; Rahm A; Taplin ME; Polascik TJ; Helfand BT; Hyatt C; Morgans AK; Feng F; Mullane M; Powers J; Concepcion R; Lin DW; Wender R; Mark JR; Costello A; Burnett AL; Sartor O; Isaacs WB; Xu J; Weitzel J; Andriole GL; Beltran H; Briganti A; Byrne L; Calvaresi A; Chandrasekar T; Chen DYT; Den RB; Dobi A; Crawford ED; Eastham J; Eggener S; Freedman ML; Garnick M; Gomella PT; Handley N; Hurwitz MD; Izes J; Karnes RJ; Lallas C; Languino L; Loeb S; Lopez AM; Loughlin KR; Lu-Yao G; Malkowicz SB; Mann M; Mille P; Miner MM; Morgan T; Moreno J; Mucci L; Myers RE; Nielsen SM; O'Neil B; Pinover W; Pinto P; Poage W; Raj GV; Rebbeck TR; Ryan C; Sandler H; Schiewer M; Scott EMD; Szymaniak B; Tester W; Trabulsi EJ; Vapiwala N; Yu EY; Zeigler-Johnson C; Gomella LG
J Clin Oncol; 2020 Aug; 38(24):2798-2811. PubMed ID: 32516092
[TBL] [Abstract][Full Text] [Related]
50. Somatic and Germline Variants Affect Prognosis and Susceptibility in Prostate Cancer.
Rocca C; Rocca G; Zampieri P; Dell'atti L; Bianchi N; Ippolito C; Aguiari G
Anticancer Res; 2023 Jul; 43(7):2941-2949. PubMed ID: 37351993
[TBL] [Abstract][Full Text] [Related]
51. Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.
Nilsson MP; Winter C; Kristoffersson U; Rehn M; Larsson C; Saal LH; Loman N
Fam Cancer; 2017 Apr; 16(2):187-193. PubMed ID: 28120249
[TBL] [Abstract][Full Text] [Related]
52. Perspective: prostate cancer susceptibility genes.
Simard J; Dumont M; Soucy P; Labrie F
Endocrinology; 2002 Jun; 143(6):2029-40. PubMed ID: 12021166
[TBL] [Abstract][Full Text] [Related]
53. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
[TBL] [Abstract][Full Text] [Related]
54. Genetic testing in women with breast cancer: implications for treatment.
Paterson R; Phillips KA
Expert Rev Anticancer Ther; 2017 Nov; 17(11):991-1002. PubMed ID: 28853307
[TBL] [Abstract][Full Text] [Related]
55. Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap.
McCuaig JM; Stockley TL; Shaw P; Fung-Kee-Fung M; Altman AD; Bentley J; Bernardini MQ; Cormier B; Hirte H; Kieser K; MacMillan A; Meschino WS; Panabaker K; Perrier R; Provencher D; Schrader KA; Serfas K; Tomiak E; Wong N; Young SS; Gotlieb WH; Hoskins P; Kim RH;
J Med Genet; 2018 Sep; 55(9):571-577. PubMed ID: 30042185
[TBL] [Abstract][Full Text] [Related]
56. A novel germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men.
Lin X; Qu L; Chen Z; Xu C; Ye D; Shao Q; Wang X; Qi J; Chen Z; Zhou F; Wang M; Wang Z; He D; Wu D; Gao X; Yuan J; Wang G; Xu Y; Wang G; Dong P; Jiao Y; Yang J; Ou-Yang J; Jiang H; Zhu Y; Ren S; Zhang Z; Yin C; Wu Q; Zheng Y; Turner AR; Tao S; Na R; Ding Q; Lu D; Shi R; Sun J; Liu F; Zheng SL; Mo Z; Sun Y; Xu J
Prostate; 2013 Jan; 73(2):169-75. PubMed ID: 22718278
[TBL] [Abstract][Full Text] [Related]
57. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
[TBL] [Abstract][Full Text] [Related]
58. DNA damage repair gene mutation testing and genetic counseling in men with/without prostate cancer: a systematic review.
Armstrong N; Quek RG; Ryder S; Ross J; Buksnys T; Forbes C; Fox KM; Castro E
Future Oncol; 2021 Mar; 17(7):853-864. PubMed ID: 33263430
[No Abstract] [Full Text] [Related]
59. Young-age prostate cancer.
Hussein S; Satturwar S; Van der Kwast T
J Clin Pathol; 2015 Jul; 68(7):511-5. PubMed ID: 25837493
[TBL] [Abstract][Full Text] [Related]
60. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
